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When an increased number of acute gastroenteritis 
(AG) cases is detected among tourists staying at the 
same accommodation, outbreak management plans 
must be activated in a timely manner to prevent 
large outbreaks. Syndromic surveillance data col-
lected between 1 January 2010 and 31 December 2013 
by five seagoing cruise ships were analysed to iden-
tify attack rate thresholds for early outbreak detec-
tion. The overall incidence rate of AG was 2.81 cases 
per 10,000 traveller-days (95% confidence interval 
(CI): 0.00–17.60), while the attack rate was 19.37 cases 
per 10,000 travellers (95% CI: 0.00–127.69). The prob-
ability of an outbreak occurring was 11% if 4 per 1,000 
passengers reported symptoms within the first 2 days 
of the voyage, and this increased to 23 % if 5 per 1,000 
passengers reported such within the first 3 days. 
The risk ratio (RR) for outbreak occurrence was 2.35, 
5.66 and 8.63 for 1, 2 and 3 days’ delay of symptoms 
reporting respectively, suggesting a dose–response 
relationship. Shipping companies’ policies and health 
authorities’ efforts may consider these thresholds for 
initiating outbreak response measures based on the 
number of cases according to day of cruise. Efforts 
should focus on ensuring travellers report symptoms 
immediately and comply with isolation measures.
Introduction 
Acute gastroenteritis (AG) is the most frequent disease 
among travellers and outbreaks are detected among 
tourists staying in accommodation every year [1], 
including on cruise ships [2]. The majority (97%) of AG 
outbreaks that were reported and diagnosed on cruise 
ships in the United States (US) during 2008–2014 were 
caused by norovirus [2]. Norovirus gastroenteritis out-
breaks often involve person-to-person and environ-
mental transmission [3-9] and have been recognised to 
have a considerable public health impact and economic 
burden on the tourism industry [10,11]. In addition to 
the public health impact and disruption of holidays, 
consequences include loss of personal travel funds 
and high ship operation costs [10]. Preventative routine 
measures include pre-embarkation screening, syndro-
mic surveillance, isolation of symptomatic travellers 
(i.e. crew members and passengers), environmental 
and personal hygiene measures, crew education, and 
instructions to travellers and others about hand wash-
ing and symptoms reporting [12,13].
Cruise ships implement syndromic surveillance of 
AG cases using standard definitions, as described in 
guidelines from the World Health Organization (WHO) 
[14], and as required by national and international 
inspection programmes for cruise ships [12,13]. For 
example, the European Manual for Hygiene Standards 
and Communicable Disease Surveillance on Passenger 
Ships includes a chapter for the prevention and con-
trol of AG, and recommends standards for syndromic 
surveillance and outbreak management plans on pas-
senger ships sailing in European Union (EU) countries’ 
waters [12]. Moreover, this manual suggests that pre-
defined thresholds for outbreak alert reports and that 
control measures should be agreed and included in the 
outbreak management plan. When increased numbers 
of AG cases are diagnosed in the ships infirmary, out-
break management plans are activated, intensifying 
the routine prevention measures and implementing 
additional ones, such as active surveillance, enhanced 
environmental disinfection, discontinuing the self-
service buffet, and social distancing [12,13]. Activating 
the outbreak management plans in a timely manner is 
important and can help to prevent the further person-
to-person transmission that results in large outbreaks 
[12,13]. However, the optimal time for initiating inten-
sive measures and activating the outbreak manage-
ment plan is under discussion and requires further 
research.
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The International Health Regulations (IHR) 2005 
requires ship captains to notify the port public health 
authority of any public health risk on board a vessel 
before arrival at the port [15]. The port health authori-
ties are responsible for checking that valid health 
and hygiene plans, including outbreak management 
plans, are in place, when notified of a risk on board. 
Shipping companies have different thresholds for ini-
tiating implementation of certain control measures in 
their plans. For example, outbreak plan activation may 
occur when there are six AG cases within 6 hours, 1% 
of passengers affected with AG on ships with less than 
1,000 passengers or 0.5% affected on ships with more 
than 1,000 passengers [12]. Some port health authori-
ties require submission of outbreak reports by a ves-
sel’s captain when certain thresholds are reached (e.g. 
first report when 2% of AG cases among passengers or 
2% among crew and a second report when 3% of AG 
cases among passengers or 3% among crew), but this 
threshold might be too high if used for determining 
the activation of outbreak management plans. A study 
by Wikswo et al. reported that infirmary surveillance 
detected only 60% of AG cases in an outbreak and sug-
gest that adjustments to outbreak reporting thresholds 
may be needed to account for incomplete voluntary 
AG reporting and to more rapidly implement control 
measures [16]. The US Centers for Disease Control and 
Prevention (CDC) Vessel Sanitation Programme (VSP) 
suggests that a 0.45% daily attack rate of AG on ships 
is indicative of a pending outbreak [13].
The objectives of this study were: (i) to analyse syn-
dromic surveillance data of AG on cruise ships in order 
to determine AG cases’ characteristics, incidence and 
attack rates for cruises with and without outbreaks, (ii) 
to identify thresholds marking levels of reported AG 
cases at which an outbreak is likely to occur at and (iii) 
to identify risk factors associated with outbreaks and 
determine possible response measures.
Methods 
Data on cases recorded in the AG surveillance logs of 
five seagoing cruise ships belonging to a single cruise 
line that conducted 760 cruises between 1 January 2010 
and 31 December 2013 were collected and analysed. 
The countries that the cruise ships visited were Cuba, 
Cyprus, Dominican Republic, Egypt, France, Greece, 
Italy, Portugal, Spain and the United Kingdom. The five 
ships implemented the same policies for surveillance 
as well as health and hygiene, including outbreak pre-
vention and management, in the 4-year period. This 
meant they followed the same rules, data collection, 
case definitions and health and hygiene management 
plans.
The cruise ships’ policies comply with the European 
Union (EU) legislation described in the European 
Manual for Hygiene Standards and Communicable 
Disease Surveillance on Passenger Ships, and the US 
VSP, both of which incorporate the global standards 
of WHO guidelines for ship sanitation [12-14,17]. Pre-
embarkation screening occurred through passenger 
completion of a one-page questionnaire on certain 
symptoms prior to boarding. In terms of hand hygiene, 
informative leaflets with hand hygiene advice were 
distributed (pillow letter), there were signs posted in 
various areas on board, including at the buffet area 
entrances, in dining rooms, in the toilet facilities and 
around hand washing sinks, that reminded passengers 
and crew to wash their hands often. Crew members 
received initial and regular refresher training on health 
and hygiene issues, and a crew member was respon-
sible for ensuring that all persons entering the buffet 
areas and dining rooms used hand antiseptic. Those 
measures intensified during outbreaks. All AG cases 
were given verbal and written advice on hand hygiene.
Acute gastroenteritis case and outbreak 
definition
The ship medical staff routinely recorded any traveller, 
which refers to both passengers and crew members, 
fulfilling the following criteria into the AG log: acute 
diarrhoea (three or more episodes of loose stools in 
a 24-hour period) or vomiting and at least one of the 
following: one or more episodes of loose stools in a 
24-hour period, abdominal cramps, headache, muscle 
aches or fever as diagnosed by the ship medical doctor 
[12,13]. Medical consultations to AG cases, as well as 
laboratory examinations were provided free of charge.
Stool samples were collected from travellers fulfill-
ing the definition of an AG case and were analysed in 
Figure 
Number of AG cases on board a cruise ship by cruise size 
and day at or above which an AG outbreak is probable, 
Cuba, Cyprus, Dominican Republic, Egypt, France, 
Greece, Italy, Portugal, Spain and the United Kingdom, 
2010–2013
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a laboratory ashore. The RIDASCREEN Norovirus 3rd 
Generation test was used, which is a qualitative enzyme 
immunoassay intended for the detection of selected 
genogroup I and genogroup II norovirus strains in 
human faeces. Specimens were taken and transported 
in accordance with the manufacturer’s instructions 
(R-Biopharm AG, Darmstadt, Germany). In addition to 
norovirus tests, stool specimens were examined by 
culture for Salmonella spp., Shigella spp., Staphylococ
cus aureus, and enteropathogenic Escherichia coli.
The data in the AG log for each cruise contained infor-
mation about cruise dates, name of all ports of call, 
number of passengers and crew numbers, number of 
travellers with AG symptoms and their age and sex, 
whether they were passengers or crew members, 
their cabin number, meal seat in the dining room and 
the date and time of symptom onset. Symptom data 
recorded in the AG log included absence or presence 
of diarrhoea and number of diarrhoea episodes, pres-
ence or absence of bloody diarrhoea, presence or 
absence of vomiting and number of vomiting episodes, 
and presence or absence of fever and temperature 
measurement results that were recorded in the AG log. 
Information on whether any stool samples were taken 
and if those samples were examined for norovirus and 
various bacterial pathogens together with their result 
were also recorded.
‘Outbreak cruises’ were considered those where ≥ 2% 
of passengers or ≥ 2% of crew members reported AG 
symptoms. ‘Non-outbreak cruises’ were considered 
those where < 2% of passengers and < 2% of crew 
reported AG symptoms. AG log data from contiguous 
Table 1
Characteristics of acute gastroenteritis cases on cruise ships and frequency of symptoms by categories of travellers, Cuba, 
Cyprus, Dominican Republic, Egypt, France, Greece, Italy, Portugal, Spain and the United Kingdom, 2010–2013 (n = 1,936)
Characteristic/ 
 
symptom of AG cases
All travellers Passengers Crew members
n or 
 
(mean)
% or 
 
(SD)
n or 
 
(mean)
% or 
 
(SD)
n or 
 
(mean)
% or 
 
(SD)
Age, years (55.2)  (18.3) (57.9) (17.1) (32.1) (9.2)
Females 1,069 55.3 995 57.6 74 35.9
Diarrhoeaa 1,815 93.7 1,616 93.6 199 96.6
Including bloody diarrhoeaa 30 1.6 26 1.5 4 1.9
Diarrhoea episodes per 24 hours (5.3) (3.6) (5.4) (3.7) (4.4) (2.7)
Vomitinga 1,207 62.4 1,097 63.5 110 53.6
Vomiting episodesa (3.9) (3.2) (4.1) (3.3) (2.9) (2.2)
Feverb 190 9.8 175 10.1 15 7.2
Fever (°C)c (38.4) (0.42) (38.4) (0.41) (38.3) (0.52)
SD: standard deviation.
a Reported by patient at the infirmary.
b Presence as diagnosed by doctor.
c Temperature as measured at the infirmary.
Table 2
Incidence rates of acute gastroenteritis per 10,000 traveller-days and attack rates for cruises with and without an outbreak, 
Cuba, Cyprus, Dominican Republic, Egypt, France, Greece, Italy, Portugal, Spain and the United Kingdom, 2010–2013 (n = 
760 cruises)
Year
Cruises without an outbreak Cruises with an outbreak
IR 
 
(cases/10,000 
traveller-days)
     95% CI      AR (cases/10,000 travellers)      95% CI     
IR (cases/10,000 
traveller-days)      95% CI     
AR 
(cases/10,000 
travellers)
     95% CI     
Overall 2.13 0.00–8.12 14.05 0.00–55.08 31.04 0.00–100.94 238.80 0.00–738.70
2010 2.85 0.00–9.74 21.28 0.00–72.05 17.95 0.00–54.22 169.08 0.00–571.24
2011 2.19 0.00–8.00 14.24 0.00–54.31 46.46 0.00–140.19 325.19 0.00–981.33
2012 1.67 0.00–6.67 10.22 0.00–39.98 9.48 0.00–28.07 138.06 0.00–428.50
2013 1.96 0.00–8.17 12.08 0.00–53.27 26.11 0.00–53.56 191.79 0.00–388.36
CI: confidence interval; IR: incidence rate.
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cruises immediately after an outbreak were excluded 
from the analysis because of the potential for the source 
of the outbreak to be associated with that of previous 
cruise. Overall attack rates and incidence rates were 
calculated per 10,000 travellers and per 10,000 travel-
ler-days respectively. Moreover, attack rates and inci-
dence rates were calculated for cruises with less than 7 
days and for more than 7 days, as well as for non-out-
break cruises and for outbreak cruises. Attack rates per 
10,000 passengers were calculated for cruises per the 
country of home port (i.e. port where most passengers 
disembark and new passengers embark).
Statistical analysis
Data analysis included descriptive statistics and uni-
variate analyses. Risk ratio (RR) was used to describe 
the association between outbreak occurrence and the 
duration of symptoms at time of reporting of AG cases. 
The Receiver Operating Characteristic (ROC) analysis 
was used for assessing the diagnostic accuracy of 
the attack rate of passenger AG cases occurring dur-
ing the first 2–3 days of a cruise and for determining 
the optimal cut-off point of the attack rate that can 
be applied to decision-making [18]. Generalised esti-
mating equations (GEE) models for logistic regression 
that are used for the analysis of longitudinal data were 
applied to estimate the daily probability of an out-
break. GEE models allow dependence within clusters. 
Table 3
Attack rates of acute gastroenteritis per 10,000 passengers for cruises by home port, 2010–2013 (n = 760)
Country of home porta Number of cruises (n) Number of AG cases (n) Total passengers (n)
Cases per 10,000 
passengers
Non-European Union countries
Cuba 2 6 330 181.82
Dominican Republic 33 149 47,116 31.62
Egypt 9 167 10,782 154.89
European Union countries
Cyprus 69 212 62,986 33.66
France 2 0 1,709 0.00
Greece 412 579 431,479 13.42
Italy 85 197 109,761 17.94
Portugal 1 10 1,286 77.76
Spain 117 518 167,246 30.97
United Kingdom 30 98 37,009 26.48
AG: acute gastroenteritis
a The port where changeover of the majority of passengers takes place.
Table 4
Risk ratio of the occurrence of an outbreak according to length of delay in acute gastroenteritis symptoms reporting by 
passengers, Cuba, Cyprus, Dominican Republic, Egypt, France, Greece, Italy, Portugal, Spain and the United Kingdom, 
2010–2013
Duration of symptoms at the time of reporting in days 
according to the day of cruise
All cruises (n = 760) Cruises ≥ 7 days long (n = 427)
RR     95% CI     p value RR     95% CI     p value
One or more passengers symptomatic for 1 day before 
reporting symptoms at any time of the cruise 2.35 2.16–2.55 < 0.001 1.90 1.75–2.06 0.005
One or more passengers symptomatic for 2 days 
before reporting symptoms at any time of the cruise 5.66 4.26–7.52 < 0.001 4.50 3.37–6.02 < 0.001
One or more passengers symptomatic for ≥ 3 days 
before reporting symptoms at any time of the cruise 8.63 5.11–14.58 < 0.001 7.03 4.12–12.03 < 0.001
One or more symptomatic passengers without 
reporting symptoms during the first 2 days of the 
cruise
2.45 0.96–6.29 0.088 2.23 0.87–5.76 0.128
One or more symptomatic passengers without 
reporting symptoms during the first 3 days of the 
cruise
3.84 2.94–5.00 < 0.001 3.55 2.70–4.69 < 0.001
CI: confidence interval; RR: risk ratio.
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All p values less than 0.05 were considered statistically 
significant. Analysis was conducted using R version 
3.0.2 Statistical Software (R Foundation for Statistical 
Computing, Vienna, Austria).
Threshold levels were calculated based on passenger-
days and reported in per 1,000 passengers because 
all outbreaks in the study occurred among passengers 
and not crew. Threshold levels were displayed graphi-
cally to show the minimum number of travellers with 
AG symptoms required for an outbreak to occur. The 
levels were obtained by the multiplication of the inci-
dence rate (per 10,000 passenger-days), the number 
of days on board, and the number of the passengers 
that a cruise may have on a journey divided by 10,000 
passenger-days.
Passenger and crew member numbers were considered 
stable throughout each cruise (i.e. it was assumed that 
no one left or got on during a single cruise). Study exit-
ing or entering during a single cruise were therefore not 
considered in the calculation of traveller-days (i.e. pas-
sengers and crew) and passenger-days.
Results 
Descriptive analysis
A total of 760 cruises, varying in size from 1,250 to 
4,000 travellers were included in the analysis. Cruise 
length ranged from 3 to 20 days, with the majority 
(56.1%) lasting 7 days. The total number of traveller 
days was 7,791,657 and the total number of passen-
gers was 869,704. Table 1 presents the characteristics 
of cases including age and sex. Age information was 
available for the 1,932 cases. A total of 55 cases among 
passengers (2.9%) were children aged < 15 years. 
Children aged < 15 years comprised 2.6% (n = 13/495) of 
the total number of cases in cruises with an outbreak 
(95%CI: 1.44–4.45) and 2.9% (n = 42/1437) in cruises 
without one (95% CI: 2.11–3.93).
During the study period, nine outbreaks of AG occurred; 
all outbreaks occurred among passengers and in 
cruises with a duration of 7 days or more. A total of 
1,936 AG cases were identified during the study period, 
with the majority (n = 1,727, 89.2%) of those occurring 
among passengers and the remaining occurring among 
the crew members.
The majority of cases presented with diarrhoea 
(93.7%), while 62.4% presented with vomiting and 
9.8% presented with fever (Table 1). Of the 1,936 
cases, 1,439 (74.3%) were examined for norovirus and 
bacterial pathogens. Of the 1,439 cases, 660 (45.8%) 
tested positive for norovirus while all tested negative 
for bacteria test results. There were at least two nor-
ovirus-positive cases for eight outbreaks, while there 
were no laboratory results available for one outbreak.
Incidence rates and attack rates
The overall incidence rate was 2.81 cases per 10,000 
traveller-days (95% CI: 0.00–17.60) while the attack 
rate was 19.37 cases per 10,000 travellers (95% CI: 
0.00–127.69). For cruises with a duration of 7 or more 
days, the overall incidence rate was 3.99 cases per 
10,000 traveller-days (95% CI: 0.00–22.53) and the 
attack rate was 30.09 cases per 10,000 travellers (95% 
CI: 0.00–169.43). The attack rate was 14.05 (95% CI: 
0.00–55.08) per 10,000 travellers for non-outbreak 
cruises and 238.80 (95% CI: 0.00–738.70) per 10,000 
travellers for outbreak cruises (Table 2). The incidence 
rate was 2.13 (95% CI: 0.00–8.12) per 10,000 travel-
ler-days for non-outbreak cruises and 31.04 (95% CI: 
0.00–100.94) per 10,000 traveller-days for outbreak 
Table 5
Probability of outbreak occurrence according to the number of acute gastroenteritis cases per 1,000 passengers during the 
first two and three days of a cruise, Cuba, Cyprus, Dominican Republic, Egypt, France, Greece, Italy, Portugal, Spain and 
the United Kingdom, 2010–2013
Number of acute 
gastroenteritis cases per 
1,000 passengers
All cruises (n = 760) Cruises ≥ 7 days long (n = 427)
  Probability of 
an outbreak (PPV, %) ROC area    95% CI   
Probability of 
an outbreak 
(PPV, %)
ROC area    95% CI   
First two days of the cruise
1 4.63
0.74 0.55–0.93
6.49
0.75 0.54–0.92
2 6.82 8.82
3 6.68 7.69
4 11.07 12.51
First three days of the cruise
1 3.50
0.87 0.72–1.00
4.83
0.87 0.71–1.00
2 7.61 9.73
3 14.64 17.14
4 22.76 25.03
5 23.10 33.37
PPV: positive predictive values; ROC: Receiver Operating Characteristic
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cruises. Considering non-outbreak cruises with a dura-
tion of 7 or more days, the overall incidence rate was 
2.90 (95% CI: 0.00–9.88) cases per 10,000 traveller-
days while the attack rate was 21.51 (95% CI: 0.00–
71.90) cases per 10,000 travellers.
The attack rate for cruises with home ports within 
Europe was 2.77 cases per 10,000 passengers, while 
the attack rate for cruises with home ports outside 
Europe was 7.04 cases per 10,000 passengers. The 
highest attack rates were recorded in cruises with home 
ports in Cuba and Egypt (Table 3). The rate ratio was 
2.54 (95% CI: 2.24–2.87), indicating that cruises with 
home ports outside Europe had 2.5 times higher attack 
rates than cruises with home ports within Europe.
Duration of symptoms at time of reporting
From the total 1,936 AG cases, 614 (31.7%) had symp-
toms for 1 day, 107 (5.5%) for 2 days and 78 (4.0%) for 
3 days or more at the time of reporting. The remaining 
cases reported their symptoms the day they occurred. 
Duration of symptoms at time of reporting (i.e. delay 
in reporting) was not associated with sex (p > 0.05) or 
age (p > 0.05). The risk of an outbreak occurring was 2.3 
times higher in cruises where one or more passengers 
delayed reporting their symptoms for 1 or more days 
(RR: 2.35, 95% CI: 2.16–2.55, p < 0.001) (Table 4). The 
RR for outbreak occurrence was 5.66 for a symptoms 
reporting delay of 2 or more days and 8.63 for 3 or more 
days. This suggests a dose–response relationship.
Outbreak probability and threshold 
determination
For the ROC analysis, the optimal cut-off point for each 
curve was found to be equal to one case per 1,000 
passengers and two cases per 1,000 passengers for 
the first 2 and 3 days, respectively (Table 5). When all 
cruises were taken into account, the probably of an 
outbreak occurring was 11.1% if four cases per 1,000 
passengers reported AG symptoms in the first 2 days 
of a cruise and 23.1% if there were five AG cases per 
1,000 passengers the first 3 days of the cruise. Only 
considering cruises with a length of 7 or more days, 
these probabilities increase to 12.5% and 33.4%, 
respectively.
The graph presents a way of showing the number of AG 
cases, according to cruise size and day of the cruise, at 
or above which an AG outbreak is probable (Figure). For 
example, if there is a cruise ship of 2,000 people, the 
cruise is on day 20, and there are 24 people reporting 
symptoms, an outbreak is probable.
Discussion 
Our retrospective study was the first attempt of the EU 
SHIPSAN ACT joint action [19,20] to cooperate with a 
cruise line and produce data-driven thresholds for out-
break prevention based on infirmary surveillance data. 
They can be used by ship operators to inform them 
when enhanced control measures should be initiated 
in their outbreak management plans. These thresholds 
can also be used by public health authorities for risk 
assessment and decision-making in terms of whether 
the number of reported cases is within the expected 
levels or not.
The collaboration of the cruise industry with the US 
CDC VSP resulted in lower numbers and severity of 
cruise ship AG outbreaks between 2008–2014 com-
pared with 2001–2004 [2,4]. The US CDC VSP receives 
reports from cruise ships with information about diar-
rheal disease cases 24–36 hours before arriving in the 
US from a foreign port and additional reports when the 
cumulative AG attack rate among either passengers 
or the crew is ≥ 2% and ≥ 3% [13]. Our study suggested 
lower triggers as indicators of a pending outbreak dur-
ing the first three days of the cruise than that of the 
US CDC VSP manual. We calculated a 33.37% probabil-
ity of having an outbreak if there are five AG cases per 
1,000 passengers within the first three days of a cruise 
on cruises of 7 days or more while the US VSP manual 
suggests a 0.45% daily attack rate (or 4.5 cases per 
1,000 passengers daily) is indicative of a pending out-
break [13]. In the future, it would be interesting to study 
surveillance data reported from different cruise lines in 
EU countries and compare those with other regions.
Incidence rates of AG in our study were higher in cruises 
with home ports outside Europe, i.e. Egypt and Cuba. 
It was not possible to examine if other factors such as 
season, passenger nationality or others affected this 
association. Moreover, this study did not show any 
indication that children could be the drivers of AG out-
breaks on board ships.
In our study the overall incidence rate was 2.81 (95% 
CI: 0.00–17.60) cases per 10,000 traveller-days, while 
the attack rate was 19.37 cases per 10,000 travellers. 
These results are similar to the recently published 
report from the US where the overall AG attack rate 
reported by cruise ships in 2008–2014 was 1.8 cases 
per 1,000 passengers and the incidence rate of AG per 
10,000 travel days ranged from 2.09 in 2013 to 2.72 in 
2008 [2].
The outbreak frequency found in our study (9 out-
breaks in 760 cruises; 1.18%) was higher than that 
from US surveillance data (133 outbreaks in 29,107 
cruises; 0.45%), but these results cannot be directly 
compared since the definition of an outbreak differed 
(≥ 2% attack rate among passengers or among crew in 
our study, ≥ 3% attack rate among passengers or among 
crew in the CDC study [2]).
According to the laboratory results, and the clinical cri-
teria, it seems that the nine AG outbreaks could have 
been caused by norovirus [21,22]. However, it should 
be noted that more than half of the cases examined for 
norovirus tested negative by immunochromatographic 
test for norovirus genogroups I and II. These results 
were not confirmed by a second molecular method, 
which might have increased the proportion of positive 
7www.eurosurveillance.org
laboratory tests [22]. Notwithstanding this, the policy 
of the company to perform microbiological analysis of 
clinical specimens of patients for norovirus and bacte-
ria aids early recognition of the aetiology of outbreaks 
and can be of value for informing decision making on 
adequate control measures.
Our study demonstrated that 31.7% of AG cases had 
symptoms for 1 day, 5.5% for 2 days and 4.0% for 3 
days or more at the time of symptom reporting. In their 
study, Wikswo et al demonstrated that 40% of respond-
ers did not report symptoms to the infirmary during an 
outbreak with 236 case passengers [16]. Considering 
such high proportions of unreported cases during out-
breaks, it could be assumed that the probabilities for 
an outbreak calculated by this study could be even 
higher. Our study also showed that the risk of an out-
break increased by 3.7-fold when there was a 3-day 
delay of symptoms reporting compared to 1-day delay. 
Future studies could examine the unreported cases 
on outbreak and non-outbreak cruises, and adjust the 
probabilities using assumptions for the numbers of 
unreported cases accordingly [16].
A retrospective survey conducted during a cruise ship 
norovirus outbreak showed that most cases delayed 
or did not report their illness to the ship’ s infirmary 
because they did not believe it was serious [23]. 
Denying of symptoms has even been reported, even 
if video surveillance data recorded public faecal acci-
dent and bringing of the towel stained with diarrhoea 
back to the pool towels bin [24]. The reasons for not 
reporting symptoms can be manifold and shipping 
companies’ policies should focus on communication 
strategies informing passengers about AG transmission 
and the importance of immediate symptoms’ reporting 
as well as the impact of AG outbreaks. Crew members 
can play an important role in prevention strategies, by 
complying with travel health and hygiene policies, and 
by actively monitoring and participating in their imple-
mentation. Furthermore, travel agents, travel health 
authorities can also help support creating awareness 
for AG-related issues and prevention.
One limitation of this study is that it analysed data from 
a single cruise line that implemented the same policy 
in all ships so it was not possible to compare epide-
miological data from different companies. To address 
this, future studies should be conducted with data 
from more ships and from different companies and 
thresholds should be based on the number of cases 
and events. Other future studies should investigate the 
association of outbreaks with itineraries and season, 
with the purpose of identifying any risk or protective 
factors.
Another limitation was that we were not able to examine 
if other factors, such as the nationality of cases, have 
an effect on AG and specifically, norovirus infection. 
Future studies may further examine this factor. Cruise 
ships are a gathering place for many nationalities and 
ethnicities and it could be worthwhile surveying asso-
ciations between these variables and risk for infection 
or outbreak occurrence. Also, it should be noted that 
in our study, the true number of symptomatic cases 
is unknown since only travellers who visited the ships 
infirmary were included in the AG log. Moreover, the 
role of asymptomatic travellers in the outbreak occur-
rence is not known.
In conclusion, this study confirmed the importance of 
aggregating and reviewing daily syndromic surveillance 
data of AG on cruise ships, particularly regarding the 
first days of the voyage, and demonstrated the impact 
of reporting delay on the occurrence of AG outbreaks 
on cruise ships. Finally, it provided specific numerical 
thresholds that should allow shipping companies and 
public health authorities to determine when an out-
break is occurring based on epidemiological evidence, 
and adjust/update their outbreak management plan-
ning accordingly.
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